This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

VIBATIV Pregnancy Registry

This study is currently recruiting participants.
See Contacts and Locations
Verified July 2017 by Theravance Biopharma Antibiotics, Inc. ( Theravance Biopharma R & D, Inc. )
Sponsor:
Information provided by (Responsible Party):
Theravance Biopharma Antibiotics, Inc. ( Theravance Biopharma R & D, Inc. )
ClinicalTrials.gov Identifier:
NCT01130324
First received: May 24, 2010
Last updated: July 18, 2017
Last verified: July 2017
  Purpose
The purpose of this registry is to evaluate the outcome of pregnancy in women exposed to VIBATIV at any time during pregnancy. There are no mandated physician visits for the registry.

Condition Intervention
Pregnancy Drug: VIBATIV

Study Type: Observational [Patient Registry]
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 9 Months
Official Title: VIBATIV (Telavancin Hydrochloride) Pregnancy Exposure Registry

Resource links provided by NLM:


Further study details as provided by Theravance Biopharma Antibiotics, Inc. ( Theravance Biopharma R & D, Inc. ):

Primary Outcome Measures:
  • Outcomes of pregnancy in women exposed to VIBATIV at any time during pregnancy [ Time Frame: Once per trimester, 6-7 months gestation, and within 4 weeks after the estimated due date ]

Secondary Outcome Measures:
  • Effect of fetal exposure to VIBATIV on pregnancy outcomes [ Time Frame: Within 4 weeks after the estimated due date and if a live infant birth is reported, at 3, 6, 9, and 12 months of age. ]
  • Fetal/neonatal outcomes [ Time Frame: Within 4 weeks after the estimated due date and if a live infant birth is reported, at 3, 6, 9, and 12 months of age. ]
  • Infant development and milestones through 12 months of age [ Time Frame: Within 4 weeks after the estimated due date and if a live infant birth is reported, at 3, 6, 9, and 12 months of age. ]

Estimated Enrollment: 300
Study Start Date: November 2009
Estimated Study Completion Date: June 2019
Estimated Primary Completion Date: June 2019 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
VIBATIV treated pregnant women
Women treated with telavancin (any dose or duration) during pregnancy.
Drug: VIBATIV
Observational
Other Names:
  • telavancin
  • TD-6424

  Eligibility

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Women exposed to VIBATIV during pregnancy and where outcome of pregnancy is unknown at time of enrollment.
Criteria

Inclusion Criteria:

  • Female patients who were exposed to VIBATIV at any time during pregnancy
  • Outcome of pregnancy is unknown at the time of enrollment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01130324

Contacts
Contact: Mia Elliott (650) 808-6444 MElliott@theravance.com
Contact: Theravance Biopharma R&D, Inc. Medical Information 1-855-633-8479

Locations
United States, California
Theravance Biopharma R&D, Inc. Recruiting
South San Francisco, California, United States, 94080
Sponsors and Collaborators
Theravance Biopharma R & D, Inc.
Investigators
Study Director: Bibiana Castaneda, MD Theravance Biopharma R & D, Inc.
  More Information

Responsible Party: Theravance Biopharma R & D, Inc.
ClinicalTrials.gov Identifier: NCT01130324     History of Changes
Other Study ID Numbers: 0113
Study First Received: May 24, 2010
Last Updated: July 18, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Keywords provided by Theravance Biopharma Antibiotics, Inc. ( Theravance Biopharma R & D, Inc. ):
VIBATIV
telavancin
Pregnancy
Registry

Additional relevant MeSH terms:
Telavancin
Anti-Bacterial Agents
Anti-Infective Agents

ClinicalTrials.gov processed this record on September 20, 2017